A single dose of Cannabidiol modulates medial temporal & striatal function during fear processing in people at clinical high risk for psychosis

Cathy Davies; Robin  Wilson; Elizabeth Appiah-Kusi; Grace Blest-Hopley; Michael Brammer; Jesus Perez; Robin M. Murray; Paul Allen; Matthijs G. Bossong; Philip McGuire; Sagnik Bhattacharyva

doi:/10.1038/s41398-020-0862-2

A single dose of Cannabidiol modulates medial temporal & striatal function during fear processing in people at clinical high risk for psychosis

Cathy Davies, Robin Wilson, Elizabeth Appiah-Kusi, Grace Blest-Hopley, Michael Brammer, Jesus Perez, Robin M. Murray, Paul Allen, Matthijs G. Bossong, Philip McGuire, Sagnik Bhattacharyva

Research output: Contribution to journal › Article › peer-review

Abstract

Emotional dysregulation and anxiety are common in people at Clinical High Risk for Psychosis (CHR) and are associated with altered neural responses to emotional stimuli in the striatum and medial temporal lobe. Using a randomised, double-blind, parallel-group design, 33 CHR patients were randomised to a single oral dose of CBD (600mg) or placebo. Healthy controls (n=19) were studied under identical conditions but did not receive any drug. Participants were scanned with functional magnetic resonance imaging (fMRI) during a fearful face-processing paradigm. Activation related to the CHR state and to the effects of CBD were examined using a region-of-interest approach. During fear processing, CHR participants receiving placebo (n=15) showed greater activation than controls (n=19) in the parahippocampal gyrus, but less activation in the striatum. Within these regions, activation in the CHR group that received CBD (n=15) was intermediate between that of the CHR placebo and control groups. These findings suggest that in CHR patients, CBD modulates brain function in regions implicated in psychosis risk and emotion processing. These findings are similar to those previously evident using a memory paradigm, suggesting that the effects of CBD on medial temporal and striatal function may be task-independent.

Original language	English
Article number	311
Journal	Translational Psychiatry
Volume	10
DOIs	https://doi.org//10.1038/s41398-020-0862-2
Publication status	Published - 13 Sept 2020

Access to Document

/10.1038/s41398-020-0862-2Licence: CC BY

https://www.nature.com/articles/s41398-020-0862-2Licence: CC BY

Cite this

Davies, C., Wilson, R., Appiah-Kusi, E., Blest-Hopley, G., Brammer, M., Perez, J., Murray, R. M., Allen, P., Bossong, M. G., McGuire, P., & Bhattacharyva, S. (2020). A single dose of Cannabidiol modulates medial temporal & striatal function during fear processing in people at clinical high risk for psychosis. Translational Psychiatry, 10, Article 311. https://doi.org//10.1038/s41398-020-0862-2

@article{319813d1d83640fe8cccc67dac880cc0,

title = "A single dose of Cannabidiol modulates medial temporal & striatal function during fear processing in people at clinical high risk for psychosis",

abstract = "Emotional dysregulation and anxiety are common in people at Clinical High Risk for Psychosis (CHR) and are associated with altered neural responses to emotional stimuli in the striatum and medial temporal lobe. Using a randomised, double-blind, parallel-group design, 33 CHR patients were randomised to a single oral dose of CBD (600mg) or placebo. Healthy controls (n=19) were studied under identical conditions but did not receive any drug. Participants were scanned with functional magnetic resonance imaging (fMRI) during a fearful face-processing paradigm. Activation related to the CHR state and to the effects of CBD were examined using a region-of-interest approach. During fear processing, CHR participants receiving placebo (n=15) showed greater activation than controls (n=19) in the parahippocampal gyrus, but less activation in the striatum. Within these regions, activation in the CHR group that received CBD (n=15) was intermediate between that of the CHR placebo and control groups. These findings suggest that in CHR patients, CBD modulates brain function in regions implicated in psychosis risk and emotion processing. These findings are similar to those previously evident using a memory paradigm, suggesting that the effects of CBD on medial temporal and striatal function may be task-independent.",

author = "Cathy Davies and Robin Wilson and Elizabeth Appiah-Kusi and Grace Blest-Hopley and Michael Brammer and Jesus Perez and Murray, {Robin M.} and Paul Allen and Bossong, {Matthijs G.} and Philip McGuire and Sagnik Bhattacharyva",

year = "2020",

month = sep,

day = "13",

doi = "/10.1038/s41398-020-0862-2",

language = "English",

volume = "10",

journal = "Translational Psychiatry",

issn = "2158-3188",

publisher = "Nature Publishing Group",

}

Davies, C, Wilson, R, Appiah-Kusi, E, Blest-Hopley, G, Brammer, M, Perez, J, Murray, RM, Allen, P, Bossong, MG, McGuire, P & Bhattacharyva, S 2020, 'A single dose of Cannabidiol modulates medial temporal & striatal function during fear processing in people at clinical high risk for psychosis', Translational Psychiatry, vol. 10, 311. https://doi.org//10.1038/s41398-020-0862-2

TY - JOUR

T1 - A single dose of Cannabidiol modulates medial temporal & striatal function during fear processing in people at clinical high risk for psychosis

AU - Davies, Cathy

AU - Wilson, Robin

AU - Appiah-Kusi, Elizabeth

AU - Blest-Hopley, Grace

AU - Brammer, Michael

AU - Perez, Jesus

AU - Murray, Robin M.

AU - Allen, Paul

AU - Bossong, Matthijs G.

AU - McGuire, Philip

AU - Bhattacharyva, Sagnik

PY - 2020/9/13

Y1 - 2020/9/13

N2 - Emotional dysregulation and anxiety are common in people at Clinical High Risk for Psychosis (CHR) and are associated with altered neural responses to emotional stimuli in the striatum and medial temporal lobe. Using a randomised, double-blind, parallel-group design, 33 CHR patients were randomised to a single oral dose of CBD (600mg) or placebo. Healthy controls (n=19) were studied under identical conditions but did not receive any drug. Participants were scanned with functional magnetic resonance imaging (fMRI) during a fearful face-processing paradigm. Activation related to the CHR state and to the effects of CBD were examined using a region-of-interest approach. During fear processing, CHR participants receiving placebo (n=15) showed greater activation than controls (n=19) in the parahippocampal gyrus, but less activation in the striatum. Within these regions, activation in the CHR group that received CBD (n=15) was intermediate between that of the CHR placebo and control groups. These findings suggest that in CHR patients, CBD modulates brain function in regions implicated in psychosis risk and emotion processing. These findings are similar to those previously evident using a memory paradigm, suggesting that the effects of CBD on medial temporal and striatal function may be task-independent.

AB - Emotional dysregulation and anxiety are common in people at Clinical High Risk for Psychosis (CHR) and are associated with altered neural responses to emotional stimuli in the striatum and medial temporal lobe. Using a randomised, double-blind, parallel-group design, 33 CHR patients were randomised to a single oral dose of CBD (600mg) or placebo. Healthy controls (n=19) were studied under identical conditions but did not receive any drug. Participants were scanned with functional magnetic resonance imaging (fMRI) during a fearful face-processing paradigm. Activation related to the CHR state and to the effects of CBD were examined using a region-of-interest approach. During fear processing, CHR participants receiving placebo (n=15) showed greater activation than controls (n=19) in the parahippocampal gyrus, but less activation in the striatum. Within these regions, activation in the CHR group that received CBD (n=15) was intermediate between that of the CHR placebo and control groups. These findings suggest that in CHR patients, CBD modulates brain function in regions implicated in psychosis risk and emotion processing. These findings are similar to those previously evident using a memory paradigm, suggesting that the effects of CBD on medial temporal and striatal function may be task-independent.

U2 - /10.1038/s41398-020-0862-2

DO - /10.1038/s41398-020-0862-2

M3 - Article

SN - 2158-3188

VL - 10

JO - Translational Psychiatry

JF - Translational Psychiatry

M1 - 311

ER -